Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study - Archive ouverte HAL Access content directly
Journal Articles Journal of Allergy and Clinical Immunology Year : 2021

Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (10) , (10) , (10) , (10)
1
2
3
4
5
6
7
8
9
10

Dates and versions

hal-03843593 , version 1 (08-11-2022)

Identifiers

Cite

Lawrence Eichenfield, Carsten Flohr, Robert Sidbury, Zsuzsanna Szalai, Ryszard Galus, et al.. Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study. Journal of Allergy and Clinical Immunology, 2021, 147 (2), pp.AB146. ⟨10.1016/j.jaci.2020.12.529⟩. ⟨hal-03843593⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More